Publication: Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates
Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates
Date
Date
Date
Citations
Curkovic, I., Egbring, M., & Kullak-Ublick, G. A. (2013). Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates. Digestive Diseases, 31(3–4), 368–373. https://doi.org/10.1159/000354699
Abstract
Abstract
Abstract
BACKGROUND: Glucocorticosteroids and aminosalicylates, mainly mesalazine (5-ASA), are both standard therapeutics in the treatment of inflammatory bowel disease (IBD) patients. The glucocorticosteroids are highly effective in inducing remission in both ulcerative colitis and Crohn's disease, but their use is limited by the high incidence and the potentially serious nature of adverse events. In an attempt to limit systemic side effects, rapidly metabolized corticosteroids such as budesonide have been introduced. The safety profile of am
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Curkovic, Ivanka
- Egbring, Marco
- Kullak-Ublick, Gerd A
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Metrics
Downloads
Views
Citations
Curkovic, I., Egbring, M., & Kullak-Ublick, G. A. (2013). Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates. Digestive Diseases, 31(3–4), 368–373. https://doi.org/10.1159/000354699
